申请人:3-Dimensional Pharmaceuticals, Inc.
公开号:US20020169200A1
公开(公告)日:2002-11-14
The present invention relates to novel substituted indole compounds that are antagonists of alpha V (&agr;v) integrins, for example &agr;
v
&bgr;
3
and &agr;
v
&bgr;
5
integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by &agr;
v
&bgr;
3
and &agr;
v
&bgr;
5
integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula:
1
where R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
, R
10
, R
11
, R
12
, R
13
, R
14
, D, X, W, a, m, n, i, j, k and v are defined herein.
本发明涉及新型取代吲哚化合物,其为αV(αv)整合素的拮抗剂,例如αvβ3和αvβ5整合素,其药学上可接受的盐以及其药物组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理性状况,包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等病症。这些化合物具有以下一般式:
1
其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、D、X、W、a、m、n、i、j、k和v在此处定义。